•
Jul 02, 2022
Masimo Q2 2022 Earnings Report
Reported strong performance in the second quarter, with revenue and earnings exceeding the high end of guidance, and raised financial guidance on a constant currency basis for fiscal year 2022.
Key Takeaways
Masimo reported consolidated revenue of $565.3 million, representing 85.3% growth compared to Q2 2021. Healthcare revenue was $357.0 million, a 17.0% increase, and non-healthcare revenue was $208.3 million. GAAP net income was $18.1 million, or $0.33 per diluted share, while non-GAAP net income was $74.8 million, or $1.35 per diluted share.
Consolidated revenue was $565 million.
Healthcare revenue was $357 million, representing 17% reported growth and 19% constant currency growth.
Non-healthcare revenue was $208 million.
Repurchased 3 million shares of Masimo common stock for $401 million.
Masimo
Masimo
Forward Guidance
The Company provided the following estimates for its third-quarter and full-year 2022 guidance:
Positive Outlook
- Third-quarter 2022 consolidated revenue is expected to be between $515 million and $545 million.
- Third-quarter 2022 healthcare revenue is expected to be between $320 million and $330 million.
- Third-quarter 2022 non-healthcare revenue is expected to be between $195 million and $215 million.
- Third-quarter 2022 consolidated earnings per diluted share are expected to be between $0.51 and $0.63 (GAAP) and $0.85 and $0.97 (Non-GAAP).
- Full-year 2022 consolidated revenue is expected to be between $1,985 million and $2,045 million.
Challenges Ahead
- For our healthcare segment, our third-quarter 2022 and full-year 2022 revenue guidance includes year-over-year foreign currency headwinds of $10 million and $30 million, respectively.
- Third-quarter 2022 GAAP net income between $27.7 million to $33.9 million
- Third-quarter 2022 Non-GAAP net income between $46.2 million to $52.3 million
- Full-year 2022 GAAP net income between $144.2 million to $157.2 million
- Full-year 2022 Non-GAAP net income between $239.9 million to $252.9 million